Evaluation of the efficacy and safety of sacubitril/valsartan in patients with hypertension combined with heart failure
10.16753/j.cnki.1008-2344.2025.06.008
- VernacularTitle:沙库巴曲缬沙坦在高血压合并心力衰竭人群中有效性及安全性评价
- Author:
Fengyan ZHANG
1
;
Jinmei REN
1
;
Yi SHEN
1
Author Information
1. 复旦大学附属中山医院青浦分院药剂科,上海 201700
- Publication Type:Journal Article
- Keywords:
sacubitril/valsartan;
hypertension;
heart failure;
effectiveness;
safety
- From:
Journal of Shenyang Medical College
2025;27(6):608-613
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of sacubitril/valsartan in the treatment of hypertension complicated with heart failure.Methods:This retrospective study included 159 patients with hypertension and heart failure who were admitted to our hospital from Jan 2022 to Sep 2023 and treated with sacubitril/valsartan.Based on whether the treatment was discontinued,the patients were divided into the discontinuation group(58 cases)and the non-discontinuation group(101 cases).The baseline characteristics of the two groups were compared,and changes in blood pressure,cardiac ultrasound parameters,and serum biomarkers before and after treatment were analyzed in 101 patients undergoing continuous treatment.Results:There were no significant differences in baseline characteristics between the two groups(P＞0.05).After 12 months of continuous treatment,systolic and diastolic blood pressure significantly decreased(P＜0.01),left atrial diameter,left ventricular end-systolic diameter,and left ventricular end-diastolic diameter were significantly reduced,left ventricular ejection fraction significantly improved(P＜0.01),and NT-proBNP level significantly decreased(P＜0.01).In the discontinuation group,65.5%of patients discontinued treatment due to adverse reactions,mainly including renal function deterioration(24.1%),hypotension(20.7%),and hyperkalemia(10.3%).The readmission rate in the discontinuation group was higher than that in the non-discontinuation group(P＜0.05).Conclusions:Sacubitril/valsartan effectively improves blood pressure control and cardiac function in patients with hypertension combined with heart failure.However,the risk of adverse reactions in specific high-risk populations warrants close monitoring in clinical practice.
